Business Context and Reporting Period
This Form 8-K was filed by Atyr Pharma, Inc. on April 7, 2017. The report discloses corporate governance changes, specifically the appointment of a new director and committee chair, effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
- Board Appointment: Timothy P. Coughlin was appointed to the Board of Directors as a Class I director, serving until the 2019 annual meeting or until a successor is elected.
- Committee Roles: Mr. Coughlin was appointed to the Audit Committee and named Chair of the Audit Committee.
- Transition: Kathryn E. Falberg, the prior Chair, will continue as a member of the Audit Committee until her term expires on May 9, 2017.
Guidance, Outlook, and Compensation
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Regarding compensation, Mr. Coughlin will receive cash and equity under the standard non-employee director policy. Specifically, he was granted an option to purchase 32,000 shares of Common Stock. The exercise price is set at the closing price on April 7, 2017, with vesting occurring in equal monthly installments over three years, contingent on continued service.
Investor Verification Checklist
- Verify the closing stock price on April 7, 2017, to determine the exercise price of the 32,000 share option granted to Mr. Coughlin.
- Review the Company's non-employee director compensation policy for details on cash compensation amounts.
- Confirm the composition of the Audit Committee following the transition from Kathryn E. Falberg to Timothy P. Coughlin.
- Check for any subsequent filings regarding Mr. Coughlin's continued service or resignation.